Advertisement
Advertisement
A researcher working in a laboratory at BeiGene's research and development centre in Beijing, China. Photo: Bloomberg
Hong Kong could become biotech listing hub, says BeiGene boss as Chinese drug maker gears up for US$1 billion flotation
The cancer treatment firm is the first to seek a secondary listing in the city since the bourse overhauled its rules in a bid to attract big technology companies
Topic |
Hong Kong Stock Exchange
Updated: 7:37am, 30 Jul, 2018
Advertisement
TOP PICKS
A researcher working in a laboratory at BeiGene's research and development centre in Beijing, China. Photo: Bloomberg
READ FULL ARTICLE
Advertisement
Advertisement
SCMP TODAY: INTL EDITION
Get updates direct to your inbox
By registering, you agree to our T&C and Privacy Policy
Thank you for your subscription.
You can also view our other newsletters.
Products & Services
Our Sites
DOWNLOAD THE SCMP APP
Copyright © 2019 South China Morning Post Publishers Ltd. All rights reserved.